Poxel Releases 2023 Universal Registration Document

Poxel SA, a biopharmaceutical company based in Lyon, France, has announced the filing of its 2023 Universal Registration Document with the French market authority, AMF. This document covers the fiscal year ending December 31, 2023, and is accessible in French on both the AMF's and Poxel's websites. An English version will follow shortly.

The document includes crucial reports such as the Annual Financial Report with the Management Report, the Corporate Governance Report, and the Corporate Social Responsibility (CSR) Report. For those preferring physical copies, printed versions are available at Poxel's headquarters in Lyon.

Poxel focuses on developing treatments for chronic diseases like non-alcoholic steatohepatitis (NASH) and rare disorders. The company is listed on Euronext Paris and maintains offices in Boston and Tokyo.